Literature DB >> 7496647

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study.

S Oehrberg1, P E Christiansen, K Behnke, A L Borup, B Severin, J Soegaard, H Calberg, R Judge, J K Ohrstrom, P M Manniche.   

Abstract

BACKGROUND: This study compared the efficacy and tolerability of paroxetine with placebo in the treatment of panic disorder.
METHOD: After three weeks of placebo, patients received 12 weeks of treatment with paroxetine (20, 40, or 60 mg) or placebo, and finally two weeks of placebo. Dosages were adjusted according to efficacy and tolerability. Standardised cognitive therapy was given to all patients. The primary measure of outcome was reduction in the number of panic attacks.
RESULTS: Analysis of the results showed statistically significant differences in favour of paroxetine between the two treatment groups in two out of the three primary measures of outcome, i.e. 50% reduction in total number of panic attacks and number of panic attacks reduced to one or zero over the study period. For the third measure of outcome, the mean change in the total number of attacks from baseline, there was a positive trend in favour of paroxetine. The results of the primary measures of outcome were strongly supported by the results of the secondary efficacy measures of outcome. In addition, paroxetine, at all doses, was very well tolerated.
CONCLUSION: Paroxetine plus cognitive therapy was significantly more effective than placebo plus cognitive therapy in the treatment of panic disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7496647     DOI: 10.1192/bjp.167.3.374

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  38 in total

Review 1.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder.

Authors:  M R Mavissakalian; J K Schmier; J A Flynn; D A Revicki
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

Review 3.  Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia.

Authors:  T A Furukawa; N Watanabe; R Churchill
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 4.  Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.

Authors:  Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Antidepressant discontinuation reactions.

Authors:  P Haddad; M Lejoyeux; A Young
Journal:  BMJ       Date:  1998-04-11

Review 6.  Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

Authors:  N S Gunasekara; S Noble; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 7.  Optimal management of anxiety in older patients.

Authors:  K J Weiss
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

8.  INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS.

Authors:  Bret R Rutherford; Veronika S Bailey; Franklin R Schneier; Emily Pott; Patrick J Brown; Steven P Roose
Journal:  Depress Anxiety       Date:  2015-10-05       Impact factor: 6.505

Review 9.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.